Clinical trials: Metastatic Neoplasm
Sarcoma
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of synovial sarcoma.
- Trial name
- NCT00052754
- Testing
- gefitinib
- Where
- 16 sites in Belgium, France and 2 more
- Volunteers
- 48 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Tumor
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT01875705
- Testing
- GDC-0994
- Where
- 4 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genentech, Inc.
Bladder Urothelial Carcinoma, Lymph Node Metastasis
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
This is a prospective, multicenter, Phase Ib clinical study designed to evaluate the safety and preliminary efficacy of propranolol combined with tislelizumab plus gemcitabine/cisplatin (GC) as neoadjuvant therapy for patients…
- Trial name
- NCT07353294
- Testing
- propranolol, Tislelizumab, gemcitabine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Cancer
Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer
To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers
- Trial name
- DISCOVER (NCT03613194)
- Testing
- Sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic
Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis
Patients with peritoneal metastasis of colorectal or high grade appendiceal origin who are candidates for cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy) will be enrolled in this study.
- Conditions
- Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
- Trial name
- NCT04157322
- Testing
- prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago
Colorectal Carcinoma
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
The purpose of this study is to evaluate and quantify the dynamic modifications of tumor blood perfusion on axitinib therapy in patients with refractory mCRC for each dose of Axitinib.
- Trial name
- AXUS (NCT01486251)
- Testing
- axitinib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Multimodality Phase II Study in Prostate Cancer
This is a single arm phase II study of docetaxel, prednisone, and sunitinib systemic therapy followed by salvage external beam radiation therapy for men who have experienced PSA recurrence following initial radical prostatectomy…
- Trial name
- NCT00734851
- Testing
- Docetaxel, Sunitinib, EBXRT
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
This phase I/II trial studies the side effects and how well localized radiation therapy or recombinant interferon beta and avelumab with or without cellular adoptive immunotherapy works in treating patients with Merkel cell…
- Trial name
- NCT02584829
- Testing
- Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Metastatic Colorectal Cancer
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer
Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer
- Trial name
- Live-RF (NCT05991102)
- Testing
- Radiofrequency electromagnetic field treatment
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Charite University, Berlin, Germany
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Leukemia, Lymphoma
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Giving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00619645
- Testing
- busulfan, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Metastatic Colorectal Cancer
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.
- Trial name
- NCT02906059
- Testing
- AZD1775, Irinotecan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- NYU Langone Health
Colorectal Neoplasms
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
The intensity of tumour response appears to be correlated with the feasibility and the duration of a therapeutic pause or of a reduced maintenance therapy maintained until progression in patients initially controlled by so-called…
- Trial name
- HIGH-LIGHT (NCT02842580)
- Testing
- 5 FLUOROURACYL, acide folinique, irinotecan
- Where
- 11 sites in France
- Volunteers
- 21 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Malignant Melanoma
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
This randomized, open-label, two period crossover study will evaluate the effect of food on the pharmacokinetics of a single dose of RO5185426 and the efficacy and safety of continuous administration in patients with BRAF V600E…
- Trial name
- NCT01264380
- Testing
- RO5185426
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Prostate Cancer, Castration Resistant
Multi-academic Center Study of Xofigo Patients
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival…
- Trial name
- NCT03419442
- Testing
- Xofigo, Taxotere, Jevtana
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bayer
Cancer
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
LVGN6051 is a humanized monoclonal antibody that specifically binds to CD137, and acts as an agonist against CD137. This first in human study of LVGN6051 is designed to establish the maximum tolerated dose (MTD) and/or the…
- Trial name
- NCT04130542
- Testing
- LVGN6051, KEYTRUDA® (pembrolizumab)
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Lyvgen Biopharma Holdings Limited
Metastatic Breast Cancer
Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer
This study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients
- Trial name
- NCT00706069
- Testing
- Vinorelbine oral, Capecitabine
- Where
- 4 sites in Greece
- Volunteers
- 40 people
- Sponsor
- Hellenic Oncology Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.